Harnessing omics data for drug discovery and development in ovarian aging

作者：Fengyu Zhang, Ming Zhu, Yi Chen, Guiquan Wang, Haiyan Yang, Xinmei Lu, Yan Li, Hsun‐Ming Chang, Yang Wu, Yunlong Ma, Shuai Yuan, Wencheng Zhu, Xi Dong, Yue Zhao, Yang Yu, Jia Wang, Liangshan Mu · 发表于：Human Reproduction Update · 年份：2025 · DOI：10.1093/humupd/dmaf002 · 被引用次数：21 · 研究领域：Reproductive Biology and Fertility、Ovarian cancer diagnosis and treatment、Epigenetics and DNA Methylation

BACKGROUND: Ovarian aging occurs earlier than the aging of many other organs and has a lasting impact on women's overall health and well-being. However, effective interventions to slow ovarian aging remain limited, primarily due to an incomplete understanding of the underlying molecular mechanisms and drug targets. Recent advances in omics data resources, combined with innovative computational tools, are offering deeper insight into the molecular complexities of ovarian aging, paving the way for new opportunities in drug discovery and development. OBJECTIVE AND RATIONALE: This review aims to synthesize the expanding multi-omics data, spanning genome, transcriptome, proteome, metabolome, and microbiome, related to ovarian aging, from both tissue-level and single-cell perspectives. We will specially explore how the analysis of these emerging omics datasets can be leveraged to identify novel drug targets and guide therapeutic strategies for slowing and reversing ovarian aging. SEARCH METHODS: We conducted a comprehensive literature search in the PubMed database using a range of relevant keywords: ovarian aging, age at natural menopause, premature ovarian insufficiency (POI), diminished ovarian reserve (DOR), genomics, transcriptomics, epigenomics, DNA methylation, RNA modification, histone modification, proteomics, metabolomics, lipidomics, microbiome, single-cell, genome-wide association studies (GWAS), whole-exome sequencing, phenome-wide association studies (PheWAS), Mendelia...